SmartNuclide is dedicated to advancing the field of nuclear medicine through the development of innovative radiopharmaceuticals aimed at improving diagnostic and therapeutic outcomes for patients, particularly those with thyroid cancer. The company has established a robust research and development pipeline that includes a variety of products such as recombinant proteins and targeted radionuclide therapies. Their focus on precision radioactive imaging utilizes advanced molecular imaging technologies like PET and SPECT, which allow for detailed visualization of organs and lesions at the molecular level. Notably, SmartNuclide has made significant strides with products like SNA002, a radioactive imaging agent targeting PD-L1, and SNA001, a recombinant human thyroid-stimulating hormone designed to aid in the treatment of differentiated thyroid cancer.

In addition to their product offerings, SmartNuclide emphasizes collaboration with academic institutions and research organizations to foster innovation in radiopharmaceutical development. The company has built several technology platforms centered around single-domain antibodies, which are integral to their diagnostic and therapeutic approaches. Their commitment to research is reflected in numerous publications in prestigious journals, showcasing their advancements in immuno-PET imaging and the efficacy of their targeted therapies. With substantial venture capital backing, SmartNuclide is positioned to become a leader in the radiopharmaceutical industry, both in China and globally.

China

SmartNuclide Biopharma is a biopharmaceutical company that focuses on discovering and developing innovative biologics used in nuclear medicine, with a world-leading research and development technology platform for domain antibody-radiopharmaceuticals.

SmartNuclide

Company Details